Recro Pharma, Inc. (REPH) Major Shareholder Sells $3,774,000.00 in Stock

Recro Pharma, Inc. (NASDAQ:REPH) major shareholder Stonepine Capital Management, sold 510,000 shares of the firm’s stock in a transaction on Friday, May 12th. The shares were sold at an average price of $7.40, for a total value of $3,774,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Stonepine Capital Management, also recently made the following trade(s):

  • On Thursday, May 11th, Stonepine Capital Management, sold 244,629 shares of Recro Pharma stock. The shares were sold at an average price of $7.65, for a total value of $1,871,411.85.
  • On Thursday, May 4th, Stonepine Capital Management, sold 217,308 shares of Recro Pharma stock. The shares were sold at an average price of $7.70, for a total value of $1,673,271.60.

Shares of Recro Pharma, Inc. (NASDAQ REPH) traded up 1.61% during midday trading on Friday, reaching $6.30. The company had a trading volume of 137,629 shares. Recro Pharma, Inc. has a 1-year low of $5.81 and a 1-year high of $12.50. The stock’s market capitalization is $120.02 million. The company’s 50-day moving average is $7.62 and its 200-day moving average is $7.69.

Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings data on Thursday, May 11th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.15. The company had revenue of $18.74 million during the quarter, compared to analysts’ expectations of $15.58 million. Recro Pharma had a negative return on equity of 61.09% and a negative net margin of 45.15%. On average, equities research analysts forecast that Recro Pharma, Inc. will post ($2.35) EPS for the current year.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

ILLEGAL ACTIVITY WARNING: “Recro Pharma, Inc. (REPH) Major Shareholder Sells $3,774,000.00 in Stock” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.themarketsdaily.com/2017/06/16/stonepine-capital-management-sells-510000-shares-of-recro-pharma-inc-reph-stock-updated-updated-updated.html.

Several equities research analysts have recently issued reports on the company. Zacks Investment Research raised Recro Pharma from a “hold” rating to a “buy” rating and set a $9.50 target price for the company in a research report on Wednesday, May 17th. Aegis reaffirmed a “buy” rating and set a $11.00 target price on shares of Recro Pharma in a research report on Monday, March 27th. Roth Capital set a $20.00 target price on Recro Pharma and gave the company a “buy” rating in a research report on Saturday, May 13th. Finally, Janney Montgomery Scott lowered Recro Pharma from a “buy” rating to a “fair value” rating and decreased their target price for the company from $21.00 to $6.50 in a research report on Wednesday. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $14.14.

A number of hedge funds have recently bought and sold shares of REPH. Janney Montgomery Scott LLC boosted its stake in Recro Pharma by 17.8% in the first quarter. Janney Montgomery Scott LLC now owns 12,485 shares of the specialty pharmaceutical company’s stock worth $109,000 after buying an additional 1,885 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Recro Pharma during the fourth quarter worth approximately $118,000. Acadian Asset Management LLC purchased a new stake in Recro Pharma during the first quarter worth approximately $150,000. Wells Fargo & Company MN boosted its stake in Recro Pharma by 3.0% in the first quarter. Wells Fargo & Company MN now owns 17,200 shares of the specialty pharmaceutical company’s stock worth $150,000 after buying an additional 500 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in Recro Pharma during the first quarter worth approximately $156,000. Institutional investors own 64.19% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply